Cleveland-based
Thermalin Diabetes, a biopharmaceutical company spun out of
Case Western Reserve University, has closed a $2.85 million A round. Funds will be used to increase production of the company's insulin analogs, continue preclinical testing and hire key individuals.
Click here to read more from MedCity News.